Acetaminophen (Paracetamol) Toxicosis

Acetaminophen (paracetamol) toxicosis is a potentially fatal poisoning syndrome in dogs and cats resulting from ingestion or administration of excessive doses of this analgesic/antipyretic drug. The condition is characterized by dose-dependent hepatotoxicity in dogs and severe methemoglobinemia with oxidative injury to erythrocytes in both species, but particularly in cats due to their deficient glucuronidation capacity. Clinical manifestations range from subclinical laboratory abnormalities to acute hepatic failure, hemolytic anemia, methemoglobinemia, and death. The toxic dose varies by species: in dogs, doses >100 mg/kg are generally considered toxic, while in cats, doses as low as 50 mg/kg can be lethal. Acetaminophen is metabolized primarily via glucuronidation and sulfation; when these pathways are saturated, a reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI), is produced, which depletes glutathione and binds to cellular proteins, causing oxidative stress and necrosis. In cats, the deficiency of glucuronosyltransferase enzymes leads to a greater proportion of the drug being metabolized via the cytochrome P450 pathway, increasing susceptibility to NAPQI formation and subsequent oxidative damage. The syndrome encompasses both hematological and hepatic manifestations, with the clinical picture varying by species, dose, and time since exposure.

The primary causative agent is acetaminophen (N-acetyl-p-aminophenol, paracetamol), a non-opioid analgesic and antipyretic commonly found in over-the-counter human medications. Toxicosis occurs when a dog or cat ingests a product containing acetaminophen, either accidentally or through inappropriate owner administration. Common sources include tablets, caplets, liquid suspensions, and combination cold/flu remedies that may also contain other toxicants (e.g., pseudoephedrine, dextromethorphan, antihistamines). The toxic dose is species-dependent: in dogs, doses of 100-200 mg/kg can cause clinical signs, with severe toxicity at >200 mg/kg; in cats, doses of 50-100 mg/kg are potentially fatal, and even 10 mg/kg can cause methemoglobinemia in some individuals. The toxic mechanism involves the metabolism of acetaminophen: at therapeutic doses, the drug is conjugated with glucuronic acid and sulfate to form inactive metabolites. When these pathways are saturated, a small fraction is oxidized by cytochrome P450 enzymes (CYP1A2, CYP2E1, CYP3A11) to form NAPQI, a highly reactive electrophile. NAPQI is normally detoxified by conjugation with glutathione. When glutathione stores are depleted, NAPQI binds to cysteine groups on cellular proteins, leading to oxidative stress, lipid peroxidation, and cell necrosis. In erythrocytes, NAPQI oxidizes hemoglobin to methemoglobin, which cannot carry oxygen, and also causes Heinz body formation and hemolysis. Cats are particularly susceptible because they have low glucuronosyltransferase activity, resulting in a higher proportion of the drug being metabolized via the P450 pathway, and they also have a more easily oxidized hemoglobin molecule.

Acetaminophen toxicosis is reported worldwide, with dogs and cats being the primary species affected. Dogs are more commonly exposed due to their indiscriminate eating habits and larger body size, but cats are more severely affected at lower doses. There is no breed or sex predilection, but young animals may be at higher risk due to accidental ingestion of medications left within reach. In cats, the toxicity is particularly severe due to their unique metabolic limitations. The incidence is higher in households where human medications are stored improperly or where owners self-medicate their pets without veterinary guidance. Seasonality is not significant, but exposure may increase during cold and flu season when acetaminophen-containing products are more commonly used by humans. Geographic variation is minimal, though regional differences in veterinary awareness and access to emergency care may influence reported outcomes. In a retrospective study of acetaminophen toxicosis in dogs and cats, the case fatality rate was approximately 20-30% in dogs and 50-60% in cats if untreated, but with prompt treatment, survival rates improve significantly.

Acetaminophen toxicosis involves a complex cascade of oxidative stress, cellular necrosis, and hematological dysfunction. After oral absorption, acetaminophen is rapidly distributed throughout the body. In therapeutic doses, it is primarily conjugated with glucuronic acid (60-70%) and sulfate (20-30%) to form non-toxic metabolites that are excreted in urine. In dogs, glucuronidation is the predominant pathway, while in cats, glucuronidation is deficient, leading to a greater reliance on sulfation and the P450 pathway. When the glucuronidation and sulfation pathways become saturated, a larger fraction of the drug is metabolized by cytochrome P450 enzymes (CYP1A2, CYP2E1, CYP3A11) to form NAPQI. NAPQI is a highly reactive electrophile that is normally detoxified by conjugation with glutathione, a tripeptide antioxidant. When glutathione stores are depleted (typically when >70% of hepatic glutathione is consumed), NAPQI binds covalently to cysteine residues on cellular proteins, leading to mitochondrial dysfunction, lipid peroxidation, and cell death. In the liver, this results in centrilobular hepatic necrosis, as the cytochrome P450 enzymes are concentrated in the centrilobular region. In erythrocytes, NAPQI oxidizes the ferrous iron (Fe2+) of hemoglobin to ferric iron (Fe3+), forming methemoglobin, which is unable to bind oxygen, leading to functional anemia and tissue hypoxia. Additionally, oxidative damage to erythrocyte membranes causes Heinz body formation (precipitated hemoglobin) and hemolysis, which can lead to anemia, hemoglobinuria, and secondary renal injury. The oxidative stress also affects other tissues, including the kidneys and central nervous system, contributing to multi-organ dysfunction. In cats, the high susceptibility is due to a combination of low glucuronosyltransferase activity, a higher proportion of the drug metabolized via the P450 pathway, and a more easily oxidized hemoglobin molecule. The clinical signs typically appear within 1-4 hours after ingestion and progress over 24-72 hours.

Several factors increase the risk and severity of acetaminophen toxicosis. Species is the most critical factor: cats are exquisitely sensitive due to their deficient glucuronidation capacity, making them susceptible to toxicity at doses as low as 50 mg/kg, whereas dogs typically require >100 mg/kg. Age may play a role, as very young animals have immature hepatic enzyme systems, potentially increasing susceptibility. Pre-existing hepatic disease or reduced glutathione stores (e.g., malnutrition, chronic illness) can exacerbate toxicity. Concurrent administration of drugs that induce cytochrome P450 enzymes (e.g., phenobarbital, corticosteroids) may increase NAPQI formation. Conversely, drugs that inhibit P450 (e.g., cimetidine) may reduce toxicity. The formulation of the product is also important: liquid suspensions may be absorbed faster, leading to more rapid onset of toxicity. The presence of other toxicants in combination products (e.g., pseudoephedrine, dextromethorphan) can complicate the clinical picture. Finally, delayed presentation to veterinary care is a major predisposing factor for poor outcome, as early treatment with N-acetylcysteine is most effective.

Clinical signs of acetaminophen toxicosis typically develop within 1-4 hours after ingestion and may progress over 24-72 hours. The severity and onset depend on the dose and species. In both dogs and cats, early signs include depression, lethargy, anorexia, vomiting, and hypersalivation. As methemoglobinemia develops, signs of tissue hypoxia become apparent: tachypnea, dyspnea, cyanosis (which may be muddy or brownish in color), and tachycardia. In cats, facial and paw edema is a characteristic feature, likely due to oxidative damage to capillaries. In dogs, hepatic injury may manifest as icterus, hepatomegaly, and signs of hepatic failure, such as vomiting, diarrhea, and abdominal pain. In severe cases, hemolysis leads to pallor, hemoglobinuria, and jaundice. Neurological signs, including ataxia, seizures, and coma, may occur due to cerebral hypoxia or hepatic encephalopathy. In peracute cases, death may occur within hours due to severe methemoglobinemia and respiratory failure. Chronic or subacute cases may present with weight loss, polyuria, polydipsia, and signs of chronic liver disease. Physical examination may reveal pale or cyanotic mucous membranes, prolonged capillary refill time, and evidence of dehydration. In cats, facial edema is often prominent, and the tongue may appear cyanotic.

The differential diagnoses for acetaminophen toxicosis include other causes of methemoglobinemia, hemolytic anemia, and acute hepatic injury. Key differentials include: (1) Other oxidant toxicities, such as onion or garlic ingestion (allium toxicosis), which also cause Heinz body hemolytic anemia and methemoglobinemia; (2) Naphthalene (mothball) toxicosis, which can cause hemolysis and methemoglobinemia; (3) Zinc toxicosis (e.g., from pennies or galvanized metal), which causes hemolytic anemia and hepatic injury; (4) Copper toxicosis (especially in Bedlington Terriers), which causes acute hepatic necrosis and hemolysis; (5) Snake envenomation (e.g., rattlesnake), which can cause coagulopathy and tissue necrosis; (6) Immune-mediated hemolytic anemia (IMHA), which presents with anemia and icterus but lacks methemoglobinemia; (7) Acute hepatitis due to infectious agents (e.g., leptospirosis, infectious canine hepatitis) or other hepatotoxins (e.g., aflatoxin, blue-green algae); (8) Hepatic lipidosis in cats, which can cause icterus and hepatic dysfunction; (9) Sepsis or systemic inflammatory response syndrome (SIRS) with multi-organ dysfunction; (10) Hypoxia from other causes, such as pulmonary disease or heart failure. Definitive diagnosis is based on history of acetaminophen exposure, characteristic clinical signs (methemoglobinemia, Heinz bodies, facial edema in cats), and response to specific therapy (N-acetylcysteine).

The diagnostic approach to suspected acetaminophen toxicosis should be systematic and rapid. Step 1: Obtain a thorough history, including any potential exposure to acetaminophen-containing products, the time of ingestion, and the dose. Step 2: Perform a complete physical examination, with particular attention to mucous membrane color (pale, cyanotic, or muddy), respiratory rate and effort, heart rate, and presence of facial edema in cats. Step 3: Immediate point-of-care testing: measure methemoglobin concentration using a co-oximeter (if available) or a bedside test; a methemoglobin level >10% is significant, and >30% is severe. Also, perform a packed cell volume (PCV) and total solids to assess anemia and hemoconcentration. Step 4: Baseline laboratory tests: complete blood count (CBC) to evaluate for Heinz bodies, anemia, and leukocytosis; serum biochemistry panel to assess liver enzymes (ALT, AST, ALP), bilirubin, glucose, and renal parameters; and urinalysis to detect hemoglobinuria or bilirubinuria. Step 5: If hepatic injury is suspected, measure serum bile acids and consider coagulation profile (PT/PTT) to assess liver function. Step 6: In cases of uncertainty, a serum or urine acetaminophen concentration can be measured, but this is not routinely available and should not delay treatment. Step 7: Imaging (thoracic radiographs, abdominal ultrasound) may be indicated to rule out other causes of respiratory distress or hepatic disease, but is not essential for diagnosis. Step 8: Initiate treatment immediately if toxicosis is suspected, even before laboratory confirmation, as early intervention is critical. The diagnosis is often confirmed by the response to N-acetylcysteine therapy.

Laboratory findings in acetaminophen toxicosis reflect oxidative injury and hepatic damage. Hematology: The CBC may show a normal or decreased PCV due to hemolysis; Heinz bodies are often visible on a blood smear, especially in cats. Methemoglobinemia is a hallmark finding, with levels >10% being significant; co-oximetry is the preferred method for measurement. Reticulocytosis may be present in later stages as the bone marrow responds to anemia. Leukocytosis may occur due to stress or inflammation. Serum biochemistry: In dogs, hepatic injury is prominent, with marked elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 24-48 hours; alkaline phosphatase (ALP) may also be elevated. Hyperbilirubinemia is common, and bilirubinuria may be present. In cats, hepatic enzyme elevations may be less pronounced, but hyperbilirubinemia and elevated liver enzymes can occur. Hypoglycemia may develop due to hepatic dysfunction. Renal parameters (BUN, creatinine) may be elevated if acute kidney injury occurs secondary to hemoglobinuria or hypotension. Electrolyte imbalances, such as hyperkalemia or hypokalemia, may occur due to hemolysis or renal dysfunction. Blood gas analysis may reveal metabolic acidosis due to lactic acidosis from tissue hypoxia. Urinalysis: Hemoglobinuria (positive for blood on dipstick but no red blood cells on sediment) is common due to hemolysis; bilirubinuria may also be present. Specific biomarkers: Serum bile acids may be elevated in cases of hepatic dysfunction. Coagulation profile may be prolonged (increased PT/PTT) in severe hepatic failure due to decreased synthesis of clotting factors.

Imaging findings in acetaminophen toxicosis are non-specific but may be useful to rule out other conditions. Thoracic radiographs may show evidence of pulmonary edema or pneumonia if aspiration has occurred, but are often unremarkable. Abdominal radiographs may reveal hepatomegaly in dogs with hepatic injury, but are not diagnostic. Abdominal ultrasonography may show a diffusely hyperechoic liver parenchyma in cases of hepatic necrosis, but this is also non-specific. In cats with facial edema, ultrasonography of the affected areas may show subcutaneous fluid accumulation. Advanced imaging such as CT or MRI is rarely indicated but may be used to evaluate for hepatic changes or cerebral edema in severe cases. Endoscopy is not useful for diagnosis. Echocardiography may be performed if cardiac disease is suspected as a cause of cyanosis, but is not necessary. Overall, imaging is of limited value in the diagnosis of acetaminophen toxicosis and should not delay treatment.

Cytological and histopathological findings are not typically required for diagnosis but can be confirmatory in fatal cases. On blood smears, Heinz bodies (small, pale, refractile inclusions on the red blood cell membrane) are a characteristic finding, especially in cats. Methemoglobinemia can be confirmed by co-oximetry. In liver biopsy, histopathology reveals centrilobular hepatic necrosis, which is characteristic of acetaminophen toxicity. The necrosis is coagulative in nature, with hepatocyte swelling, vacuolation, and nuclear pyknosis. In severe cases, there may be bridging necrosis and collapse of the reticulin framework. In the kidneys, tubular necrosis may be present due to hemoglobinuria and ischemia. In cats, pulmonary edema and subcutaneous edema may be noted on histopathology. Special stains, such as Prussian blue for iron, may be used to rule out other causes of hepatic necrosis. However, histopathology is rarely performed antemortem due to the risk of bleeding in coagulopathic patients.

Treatment of acetaminophen toxicosis is a medical emergency and should be initiated immediately upon suspicion. The goals are to prevent further absorption, provide specific antidotal therapy, and manage clinical signs. Emergency stabilization: If the patient is in respiratory distress, provide supplemental oxygen. If methemoglobinemia is severe (>30%) and the patient is symptomatic, consider methylene blue (in dogs only; contraindicated in cats due to risk of Heinz body hemolysis). However, N-acetylcysteine (NAC) is the primary antidote and should be given as soon as possible. Decontamination: If ingestion occurred within 1-2 hours, induce emesis (in dogs) or perform gastric lavage (in cats, if indicated) after stabilizing the airway. Activated charcoal (1-2 g/kg PO) can be administered to bind unabsorbed drug, but should be given with a cathartic (e.g., sorbitol) to prevent constipation. Specific antidotal therapy: N-acetylcysteine (NAC) is the cornerstone of treatment. It acts as a glutathione precursor and directly reduces NAPQI. The recommended dosage is a loading dose of 140 mg/kg IV or PO, followed by 70 mg/kg every 6 hours for 7 doses (or as per specific protocols). In dogs, NAC can be given IV slowly over 20 minutes; in cats, oral administration may be preferred to avoid vomiting, but IV is also used. NAC has a strong sulfur odor and may cause vomiting; antiemetics (e.g., maropitant 1 mg/kg SC) may be used. Ascorbic acid (vitamin C) is also recommended, especially in cats, at a dose of 30 mg/kg PO or IV every 6 hours for 4-6 treatments, as it helps reduce methemoglobin. Methylene blue (1-2 mg/kg IV) can be used in dogs for severe methemoglobinemia, but is contraindicated in cats. Supportive care: Intravenous fluids (e.g., lactated Ringer's solution) should be administered to maintain hydration and renal perfusion. Hepatoprotectants such as S-adenosylmethionine (SAMe) (18 mg/kg PO q24h) and silymarin (milk thistle) may be beneficial. Antiemetics (maropitant 1 mg/kg SC q24h) and gastroprotectants (e.g., famotidine 0.5-1 mg/kg IV/PO q12h) may be used. In cases of severe anemia (PCV <20%), blood transfusion may be necessary. Oxygen therapy is indicated for hypoxic patients. In cats with facial edema, cold compresses may provide comfort. Monitoring: Serial methemoglobin levels, PCV, liver enzymes, and clinical status should be monitored every 6-12 hours initially. Treatment should continue until methemoglobin levels are <10% and clinical signs resolve.

The prognosis for acetaminophen toxicosis depends on the dose, species, time to treatment, and severity of clinical signs. With prompt and aggressive treatment, the prognosis is generally good, especially in dogs. In cats, the prognosis is more guarded due to their increased susceptibility. Mortality rates are reported to be 20-30% in dogs and 50-60% in cats if untreated, but with early NAC therapy, survival rates exceed 80% in both species. Negative prognostic indicators include: severe methemoglobinemia (>50%), severe anemia (PCV <20%), marked hepatic enzyme elevation (ALT >1000 U/L), coagulopathy, neurological signs, and delayed treatment (>12 hours post-ingestion). Patients that survive the acute phase may have residual hepatic dysfunction, but this is usually reversible. In cats, facial edema typically resolves within 24-48 hours with treatment. Long-term prognosis is excellent if the patient survives the initial 72 hours.

Follow-up care is essential to monitor recovery and detect complications. Patients should be re-examined at 24, 48, and 72 hours after initiation of treatment. Serial blood work should include PCV, methemoglobin level, liver enzymes (ALT, AST, ALP), bilirubin, and renal parameters. Once the patient is stable, re-check liver enzymes at 1 week and 2 weeks post-treatment to ensure resolution of hepatic injury. If hepatic enzyme elevations persist, further evaluation (e.g., bile acids, ultrasound) may be indicated. Owners should be advised to monitor for signs of liver failure (e.g., icterus, vomiting, lethargy) and to avoid any further exposure to acetaminophen. In cats, a recheck at 1 month may be recommended to assess for chronic kidney disease secondary to hemoglobinuria. Long-term management may include a hepatoprotective diet and supplements (SAMe, vitamin E) if hepatic injury was severe. Owners should be educated on the dangers of human medications and the importance of storing them securely.

Pearls: (1) Always consider acetaminophen toxicosis in any cat or dog presenting with acute methemoglobinemia, especially if there is a history of exposure to human medications. (2) Methemoglobinemia causes a 'muddy' or chocolate-brown color to mucous membranes, which is distinct from cyanosis. (3) Cats are exquisitely sensitive; even a single extra-strength tablet (500 mg) can be fatal. (4) N-acetylcysteine is most effective when given within 8 hours of ingestion, but should still be given even if delayed. (5) Methylene blue is contraindicated in cats because it can exacerbate Heinz body hemolysis. (6) Heinz bodies are a hallmark finding on blood smear, especially in cats. (7) Facial and paw edema in cats is a classic sign and may be mistaken for allergic reaction. Pitfalls: (1) Do not wait for laboratory confirmation to start NAC; treatment should be initiated based on history and clinical signs. (2) Do not use activated charcoal without a cathartic, as it can cause constipation and delay elimination. (3) Avoid using methylene blue in cats. (4) Do not underestimate the severity of toxicity in cats; even low doses can be lethal. (5) Do not forget to monitor for hypoglycemia and provide dextrose supplementation if needed. (6) Do not discharge the patient prematurely; hepatic injury may peak at 48-72 hours. (7) Do not use acetaminophen as an analgesic in cats at any dose.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: (1) N-acetylcysteine (NAC): Loading dose 140 mg/kg IV or PO, followed by 70 mg/kg every 6 hours for 7 doses. In dogs, IV administration should be slow (over 20 minutes) to avoid vomiting; in cats, oral administration is preferred if tolerated. NAC can be diluted in 5% dextrose to reduce phlebitis. (2) Ascorbic acid (vitamin C): 30 mg/kg PO or IV every 6 hours for 4-6 treatments, especially in cats. (3) Methylene blue (dogs only): 1-2 mg/kg IV over 5-10 minutes, repeated if necessary, but do not exceed 4 mg/kg total. Contraindicated in cats. (4) Activated charcoal: 1-2 g/kg PO, mixed with water, with a cathartic (e.g., sorbitol 3 g/kg) if not contraindicated. (5) Maropitant (Cerenia): 1 mg/kg SC or PO q24h for vomiting. (6) Famotidine: 0.5-1 mg/kg IV or PO q12h for gastric protection. (7) S-adenosylmethionine (SAMe): 18 mg/kg PO q24h as a hepatoprotectant. (8) Silymarin (milk thistle): 20-50 mg/kg PO q24h. (9) Intravenous fluids: Lactated Ringer's solution at maintenance rates (60-100 ml/kg/day) adjusted for dehydration and ongoing losses. (10) Oxygen therapy: As needed for hypoxia. (11) Blood transfusion: If PCV <20% and clinical signs of anemia. (12) Dextrose supplementation: If hypoglycemic, add 2.5-5% dextrose to IV fluids. All dosages should be adjusted based on renal or hepatic function, and drug interactions should be considered (e.g., NAC may interact with activated charcoal, reducing its absorption).

The literature on acetaminophen toxicosis in dogs and cats is extensive. Key studies include: (1) A retrospective study by Sellon et al. (2009) in the Journal of Veterinary Emergency and Critical Care evaluated 100 cases of acetaminophen toxicosis in dogs and cats, reporting that cats had a higher mortality rate and that early treatment with NAC improved survival. (2) A study by Savides et al. (1984) in the American Journal of Veterinary Research demonstrated the efficacy of NAC in preventing hepatic necrosis in dogs. (3) A study by Court and Greenblatt (2000) in the Journal of Veterinary Pharmacology and Therapeutics highlighted the species differences in acetaminophen metabolism, explaining the increased susceptibility of cats. (4) A consensus statement from the American College of Veterinary Emergency and Critical Care (ACVECC) on the management of toxicoses recommends NAC as the primary antidote and emphasizes the importance of early intervention. (5) A study by Richardson (2000) in Veterinary Clinics of North America: Small Animal Practice reviewed the clinical management of acetaminophen toxicosis, providing detailed protocols for NAC and supportive care. (6) A recent study by Lee et al. (2017) in the Journal of Veterinary Medical Science evaluated the use of ascorbic acid as an adjunctive therapy in cats, showing a reduction in methemoglobin levels. Overall, the evidence strongly supports the use of NAC, aggressive supportive care, and close monitoring to improve outcomes.